Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Metformin Hydrochloride in Diabetes Mellitus, Type 2: ACTRN12626000800325 Clinical Landscape Report 2026
15 October 2026
ACTRN12626000800325 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Semaglutide (Novo Nordisk) in Diabetes Mellitus, Type 2: NCT07677995 Clinical Landscape Report 2026
15 October 2026
NCT07677995 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Montelukast sodium in Kidney Diseases: NCT07685886 Clinical Landscape Report 2026
15 October 2026
NCT07685886 clinical landscape for Kidney Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HS-10504 in Non-Small Cell Lung Cancer: NCT07685041 Clinical Landscape Report 2026
15 October 2026
NCT07685041 clinical landscape for Non-Small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Non-Small Cell Lung Cancer: NCT07683832 Clinical Landscape Report 2026
15 October 2026
NCT07683832 clinical landscape for Non-Small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in MSS/pMMR/MSI-L Rectal Carcinoma: NCT07687875 Clinical Landscape Report 2026
15 October 2026
NCT07687875 clinical landscape for MSS/pMMR/MSI-L Rectal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AN4035 in CEACAM5 positive non-squamous non-small cell lung cancer: NCT07686445 Clinical Landscape Report 2026
15 October 2026
NCT07686445 clinical landscape for CEACAM5 positive non-squamous non-small cell lung cancer: endpoints, sponsor, phase, geography, readouts, asset context an…
9 min read
Senolytics in Squamous cell carcinoma of the oral cavity: CTRI/2026/07/113613 Clinical Landscape Report 2026
15 October 2026
CTRI/2026/07/113613 clinical landscape for Squamous cell carcinoma of the oral cavity: endpoints, sponsor, phase, geography, readouts, asset context and deve…
9 min read
Imeglimin Hydrochloride in Diabetes Mellitus, Type 2: NCT07691177 Clinical Landscape Report 2026
15 October 2026
NCT07691177 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Capecitabine in Colorectal Cancer: TCTR20260710011 Clinical Landscape Report 2026
15 October 2026
TCTR20260710011 clinical landscape for Colorectal Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Empagliflozin/Linagliptin/Metformin Hydrochloride in Diabetes Mellitus, Type 2: NCT07691203 Clinical Landscape Report 2026
15 October 2026
NCT07691203 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Empagliflozin/metformin Hydrochloride in Diabetes Mellitus, Type 2: NCT07694115 Clinical Landscape Report 2026
15 October 2026
NCT07694115 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.